NCT02310477 2026-03-13
REBECCA
Centre Oscar Lambret
Completed
Clinical Trials
22 trialsNCT06137170 2026-03-02
RegoSeq
Bayer
Completed
NCT05839951 2025-11-12
STAR-T
Bayer
Completed
NCT05713994 2025-03-25
CCGLC-001
Tongji Hospital
Recruiting
NCT06029010 2025-02-26
COLONGER
Bayer
Completed
NCT04810182 2024-02-08
Regorafenib in Patients With Relapsed Glioblastoma. IOV-GB-1-2020 REGOMA-OSS
Istituto Oncologico Veneto IRCCS
Completed
NCT05594147 2023-11-07
ROCURS
Bayer
Completed
NCT05993702 2023-08-15
TAS-102 in Combination With Regorafenib or Fruquintinib for Third-line and Above Advanced Colorectal Cancer
China Medical University, China
Unknown
NCT02106858 2023-07-24
StivargaPMS
Bayer
Completed
NCT05942768 2023-07-12
Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite Stable Metastatic Colorectal Cancer
Hunan Cancer Hospital
Completed
NCT03289273 2023-06-13
Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)
Bayer
Completed
NCT05811481 2023-04-13
ROSE
First Affiliated Hospital, Sun Yat-Sen University
Unknown
NCT05557656 2022-12-29
A Real World Study of Regogfinib in HCC
Zhongda Hospital
Unknown
NCT03829852 2021-07-23
Regorafenib in Taiwan Metastatic Colorectal Cancer (mCRC) Patients
Taipei Veterans General Hospital, Taiwan
Completed
NCT04771715 2021-02-25
Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer
Peking Union Medical College Hospital
Unknown
NCT03644511 2020-08-21
SORAGO-HCC
Bayer
Terminated
NCT04431791 2020-06-16
Real World Study of Regorafenib Versus Fruquintinib in Colorectal Cancer
Peking University
Unknown
NCT02347852 2018-09-10
REGO-ACT
Bayer
Completed
NCT01843400 2018-08-02
Regorafenib Post-marketing Surveillance
Bayer
Completed
NCT03386825 2018-05-15
COLONG
Bayer
Completed
NCT02656524 2018-02-12
Stivarga Real Life Evidence in Hungary
Bayer
Completed
NCT02042144 2018-01-16
Correlate
Bayer
Completed